Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novel Pharmaceutical Drug is an investigational plant-based therapeutic being developed by Evithé Biotechnology for the treatment of acute inflammation and as an antibiotic synergist. Currently in Phase 1 clinical development, the drug is part of a platform of novel plant-derived compounds designed to modulate key inflammatory and immune mediators. Its mechanism of action involves the inhibition or modulation of Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Nitric Oxide, as well as the modulation of immunoglobulin G (IgG) and immunoglobulin M (IgM) levels. By targeting these pathways, the drug aims to provide potent anti-inflammatory effects and enhance the efficacy of antibiotics, potentially addressing conditions where inflammation and bacterial resistance are significant challenges.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Novel Pharmaceutical Drug.